Eli Lilly Must Pay Royalties In Diabetes Drug Row, Judge Says

By Andrew Karpan · October 20, 2021, 8:53 PM EDT

A federal judge has determined that Eli Lilly owes an Arizona company a portion of the billions of dollars in sales from its insulin brands, citing a 1992 royalty agreement that...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Opinion

Case Information

Case Title

Research Corporation Technologies Incorporated v. Eli Lilly and Company

Case Number

Court

Arizona

Nature of Suit

Contract: Other

Date Filed

April 04, 2016

Recent Articles By Andrew

April 30, 2025
Judge Keeps Pfizer Foe's COVID Vaccine Patent Case Alive
April 29, 2025
Fed. Circ. Backs TM Denial Of Dark Green Gloves As Generic
April 25, 2025
Judge Says FDA Can Take Ozempic Off Shortage List
March 28, 2025
Doctor's Counterclaims Cut In 'Groq' TM Feud With Chipmaker
March 21, 2025
Novartis Urges Court To Make FDA Block Entresto Generic
March 18, 2025
ITC To Review Whether Tourniquet Importers Are Ignoring Ban
March 17, 2025
New Bills Target 'Patent Thickets' And 'Product Hopping'
February 24, 2025
Patent Eligibility Appeals 'Will Not Go Away,' Justices Told
February 12, 2025
Labcorp Can't Score New Trial After $384M Patent Loss
February 06, 2025
Drug Cos. Urge Full Fed. Circ. To Hear Teva Orange Book Row